Inspire Medical Systems' Q2 2025: Key Contradictions on Revenue Growth, Medicare Billing, and Patient Trends
Generated by AI AgentAinvest Earnings Call Digest
Monday, Aug 4, 2025 11:32 pm ET1min read
INSP--
Aime Summary
Inspire V transition and impact on revenue, Medicare billing and revenue impact, impact of GLP-1s on patient volume, patient flow and utilization trends, Inspire V transition and patient flow are the key contradictions discussed in Inspire Medical Systems' latest 2025Q2 earnings call.
Inspire V Launch Challenges and Revenue Guidance Adjustment:
- Inspire Medical SystemsINSP-- faced challenges with the rollout of the Inspire V system, resulting in a 4% reduction in full-year revenue guidance to $900 million to $910 million from $940 million to $955 million.
- The challenges included a slower-than-expected transition of centers to Inspire V, billing delays for Medicare patients, and increased marketing and footprint expansion costs.
Patient Flow and Surgery Complexity Reduction:
- U.S. centers that have transitioned to Inspire V experienced a more than 20% increase in patient implants in the first half of 2025 compared to the same period in 2024.
- This increase was attributed to reduced surgical complexity with Inspire V, eliminating the need for a pressure sensing lead, which improved surgeon capacity.
Mandatory Center Training and Software Updates:
- Many centers did not complete the required training, implementation of SleepSync, and onboarding criteria before the purchase and implant of Inspire V.
- This delay contributed to the slower-than-expected transition to the new system, as the approval process from centers' IT departments took longer than expected.
Medicare Billing and CPT Code Adoption:
- The approval of CPT code 64568 for Inspire V for Medicare patients was announced in April, with a retroactive effective date of January 1, 2025.
- However, the software updates for claims submissions and processing did not take effect until July 1, delaying the ability of centers to bill procedures involving Medicare patients.
Inspire V Launch Challenges and Revenue Guidance Adjustment:
- Inspire Medical SystemsINSP-- faced challenges with the rollout of the Inspire V system, resulting in a 4% reduction in full-year revenue guidance to $900 million to $910 million from $940 million to $955 million.
- The challenges included a slower-than-expected transition of centers to Inspire V, billing delays for Medicare patients, and increased marketing and footprint expansion costs.
Patient Flow and Surgery Complexity Reduction:
- U.S. centers that have transitioned to Inspire V experienced a more than 20% increase in patient implants in the first half of 2025 compared to the same period in 2024.
- This increase was attributed to reduced surgical complexity with Inspire V, eliminating the need for a pressure sensing lead, which improved surgeon capacity.
Mandatory Center Training and Software Updates:
- Many centers did not complete the required training, implementation of SleepSync, and onboarding criteria before the purchase and implant of Inspire V.
- This delay contributed to the slower-than-expected transition to the new system, as the approval process from centers' IT departments took longer than expected.
Medicare Billing and CPT Code Adoption:
- The approval of CPT code 64568 for Inspire V for Medicare patients was announced in April, with a retroactive effective date of January 1, 2025.
- However, the software updates for claims submissions and processing did not take effect until July 1, delaying the ability of centers to bill procedures involving Medicare patients.
Descubre qué cosas son las que los ejecutivos no quieren revelar durante las llamadas de conferencia.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet